Clinical trials: Stage I Skin Cancer
Breast Cancer
Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
The investigators plan to study the efficacy of the combination of weekly paclitaxel + BIBF 1120 in early breast cancer using a neoadjuvant schedule and a randomized phase-II trial design, comparing the efficacy vs.
- Trial name
- NCT01484080
- Testing
- BIBF + Paclitaxel, Paclitaxel
- Where
- 3 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Sarcoma, Kaposi, HIV Infections
A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma
To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections.
- Trial name
- NCT00002262
- Testing
- Tumor Necrosis Factor
- Where
- United States
- Sponsor
- University of California, San Francisco
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Breast Cancer, Breast Cancer Metastatic
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without [adjuvant], in patients with human epidermal growth factor receptor 2 (HER2)…
- Trial name
- NCT06746688
- Testing
- ES2B-C001, ISA 51 VD
- Where
- 3 sites in Austria
- Volunteers
- 40 people
- Sponsor
- ExpreS2ion Biotechnologies
Recurrent Melanoma, Stage III Melanoma
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
RATIONALE: White blood cells that have been treated in a laboratory may be able to kill tumor cells in patients with melanoma. Aldesleukin and denileukin diftitox may stimulate the white blood cells to kill melanoma cells.
- Conditions
- Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT00945269
- Testing
- therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002460
- Testing
- goserelin acetate, tamoxifen citrate, ablative endocrine surgery
- Where
- 34 sites in Belgium, United Kingdom
- Sponsor
- Cancer Research UK
Melanoma (Skin), Melanoma, Stage II, Stage I
Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma
A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app.
- Conditions
- Melanoma (Skin), Melanoma, Stage II, Stage I, Melanoma Stage, Survivorship
- Trial name
- Melanoma SCP (NCT06643286)
- Testing
- Digizorg Melanoma app
- Where
- 4 sites in Netherlands
- Volunteers
- 180 people
- Sponsor
- Erasmus Medical Center
Early Breast Cancer
A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)
This study involves a two-part design. Part 1 is designed to determine the optimal dose of subcutaneous (SC) Perjeta, injected alone or mixed with Herceptin, that results in comparable exposure to intravenous (IV) Perjeta.
- Trial name
- NCT02738970
- Testing
- Trastuzumab, Pertuzumab
- Where
- 2 sites in New Zealand
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Stage I Breast Cancer, Stage II Breast Cancer
Exercise Program for Early Breast Cancer Survivors
Rationale: Exercise therapy may improve the quality of life of breast cancer survivors. Purpose: This randomized clinical trial studies exercise therapy and quality of life in postmenopausal early breast cancer survivors…
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01140282
- Testing
- questionnaire administration, quality-of-life assessment, management of therapy complications
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- University of Southern California
Breast Cancer
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
The SAFE-DE study investigates whether circulating tumour DNA (ctDNA) testing can guide adjuvant treatment decisions in patients with stage I breast cancer, identifying those who may be able to avoid chemotherapy after surgery.
- Trial name
- Safe-De (NCT05058183)
- Testing
- ctDNA
- Where
- 13 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma, Effects of Immunotherapy
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
The prognosis of advanced metastatic melanoma remains poor although a breakthrough has been achieved with the novel anti-CTLA-4 treatment (ipilimumab) for a subset of patients.
- Conditions
- Melanoma, Effects of Immunotherapy, Adverse Effect of Radiation Therapy
- Trial name
- NCT02406183
- Testing
- Stereotactic body radiotherapy (SBRT), Ipilimumab
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- Radiotherapie
Breast Cancer
Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
The study includes Phase I dose escalation and expansion and Phase II combination therapy. It uses a multicenter, open-label, non-randomized design to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy…
- Trial name
- NCT07697443
- Testing
- TQB3126
- Where
- 6 sites in China
- Volunteers
- 300 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Cancer, Breast Cancer
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in…
- Conditions
- Colorectal Cancer, Breast Cancer, Pancreas Cancer, Ovarian Cancer
- Trial name
- NCT04640480
- Testing
- SNB-101
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- SN BioScience
Malignant Melanoma
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
IMCgp100 is a new biological therapy designed for the treatment of melanoma skin cancer. The drug is designed to target melanoma cells and stimulate immune cells to kill them.
- Trial name
- NCT01211262
- Testing
- IMCgp100
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 84 people
- Sponsor
- Immunocore Ltd
Breast Cancer
Chemotherapy in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of annamycin liposomal in treating patients who have…
- Trial name
- NCT00012129
- Testing
- liposomal annamycin
- Where
- United States
- Sponsor
- NYU Langone Health
Cutaneous T-Cell Lymphomas
Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome
Hypothesis: Addition of low dose TSEBT to debulk MF/SS either before or during checkpoint blockade with anti-PD-1 pembrolizumab monoclonal antibody therapy will be safe and well tolerated.
- Trial name
- NCT03617224
- Testing
- TSEBT, TSEBT and pembrolizumab
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Triple-Negative Breast Cancer, Breast Cancer
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer
- Trial name
- NCT02393794
- Testing
- Romidepsin, Cisplatin, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 51 people
- Sponsor
- Priyanka Sharma
Malignant Melanoma, Neoplasms
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
This open-label, multicenter, parallel study will evaluate the effect of multiple doses of vemurafenib on the pharmacokinetics of a single dose of phenprocoumon in patients with BRAFV600 mutation-positive metastatic malignancies.
- Trial name
- NCT01849666
- Testing
- phenprocoumon, vemurafenib
- Where
- 17 sites in Belgium, Finland and 3 more
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Metastatic Cancer, Metastatic Melanoma
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Background: A new cancer treatment involves collecting white blood cells from an individual, modifying them to secrete IL-2 and target the ESO-1 protein expressed on some cancers, and returning them to the body.
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer
- Trial name
- NCT01457131
- Testing
- Fludarabine, Cyclophosphamide, IL-12 & Anti-NY ESO1 TCR PBL
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.